SCHEMBL19974913

SCHEMBL19974913

CC(C(O)C(=O)NCC1CC1)N(C)C(=O)C1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
GAA P10253 2/20 0.38
TSHR P16473 2/20 0.36
CTSL P07711 1/20 0.36
CTSB P07858 1/20 0.36
CTSK P43235 1/20 0.36
KMT2A Q03164 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
MEN1 O00255 1/20 0.36
EPHX2 P34913 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP3 P08254 1/20 0.35
MMP9 P14780 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974966 0.95 SMN1; SMN2 (0.44) EPHX1SMN1; SMN2ALDH1A1L3MBTL1GAA
SCHEMBL19975216 0.82 SMN1; SMN2 (0.44) EPHX1SMN1; SMN2ALDH1A1L3MBTL1GAA
SCHEMBL19975309 0.81 SMN1; SMN2 (0.44) EPHX1SMN1; SMN2ALDH1A1L3MBTL1GAA
SCHEMBL19975197 0.80 TDP1 (0.37) SMN1; SMN2ALDH1A1L3MBTL1GAATSHR
SCHEMBL19974824 0.78 SMN1; SMN2 (0.41) EPHX1SMN1; SMN2ALDH1A1L3MBTL1GAA
SCHEMBL19975201 0.77 EPHX1 (0.44) EPHX1SMN1; SMN2ALDH1A1L3MBTL1GAA
SCHEMBL19975563 0.75 EPHX1 (0.53) EPHX1SMN1; SMN2ALDH1A1TSHRCTSL
SCHEMBL19975527 0.75 ADH1C (0.46) EPHX1SMN1; SMN2ALDH1A1L3MBTL1GAA
SCHEMBL19975400 0.74 SMN1; SMN2 (0.40) EPHX1SMN1; SMN2ALDH1A1L3MBTL1GAA
SCHEMBL19974838 0.74 SMN1; SMN2 (0.40) EPHX1SMN1; SMN2ALDH1A1L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
CN-110062753-A Antiviral compounds 哈普洛根有限责任公司 2019-07-26 CN disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C EPHX1 372/4885SMN1; SMN2 706/4885ALDH1A1 2271/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C EPHX1 449/4885SMN1; SMN2 1086/4885ALDH1A1 2673/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C EPHX1 372/4885SMN1; SMN2 706/4885ALDH1A1 2271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.